ENTA News and Press, Enanta Pharmaceuticals Inc. From 05/10/20

Moderna Receives FDA Approval for Phase 2 Studies, Reports Q1 Results Moderna (MRNA) reported that the FDA has given approval for the start of Phase 2 trial of its Coronovirus vaccine, mRNA-1273. The company is now looking to begin the trial at the earliest. Moderna also reported its Q1 f...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2020 Earnings Conference Call May 6, 2020 16:30 ET Company Participants Jennifer Viera - Senior Director, IR Jay Luly - President & CEO Paul Mellett - CFO Nathalie Adda - SVP & CMO Conference Call Participants Yasmeen Rahimi ...

Image source: The Motley Fool. Enanta Pharmaceuticals Inc   (NASDAQ: ENTA) Q2 2020 Earnings Call May 6, 2020 , 4:30 p.m. ET Operator Continue reading

A Phase 2 clinical trial, INTREPID , evaluating Enanta Pharmaceuticals' (NASDAQ: ENTA ) EDP-305 in patients with a bile duct disorder called primary biliary cholangitis  (PBC), failed to achieve the primary endpoint of a statistically significant proportion of treated patients experie...

Enanta Pharma (NASDAQ: ENTA ): Q2 GAAP EPS of -$0.30 beats by $0.43 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

On Track to Initiate Phase 1b Study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020 Royalty Revenue for the Quarter was $27.6 Million Cash and Marketable Securities Totaled $435.4 Million at March 31, 2020 Enanta Pharmaceut...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor (FXR), in subjects with pri...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 202...

TherapeuticsMD Provides Business Updates, Suspends Guidance Due to COVID 19 TherapeuticsMD ( TXMD ) announced important updates about its business operations including introducing cost reduction initiatives. The company also stated that it has decided to suspend its guidance for FY 2020....